[{"id":"df568c08-818e-4e88-a7ec-38377deb4c56","acronym":"","url":"https://clinicaltrials.gov/study/NCT07162051","created_at":"2025-09-13T08:42:14.196Z","updated_at":"2025-09-13T08:42:14.196Z","phase":"Phase 2","brief_title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT07162051","lead_sponsor":"Xijing Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-09-09"},{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"8537fc07-b20e-4627-9a1d-e044da2ecc29","acronym":"","url":"https://clinicaltrials.gov/study/NCT06541314","created_at":"2025-02-26T08:14:03.914Z","updated_at":"2025-02-26T08:14:03.914Z","phase":"Phase 2","brief_title":"Fluzoparib Neoadjuvant Therapy for Ovarian Cancer","source_id_and_acronym":"NCT06541314","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/18/2024","start_date":" 06/18/2024","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-11-27"},{"id":"1455a292-12e3-4ee4-837b-54ea7dad02d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06533384","created_at":"2025-02-27T07:58:59.217Z","updated_at":"2025-02-27T07:58:59.217Z","phase":"Phase 3","brief_title":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","source_id_and_acronym":"NCT06533384","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-11-04"},{"id":"066af9ab-9fbe-40c8-8b39-9e712dd6f439","acronym":"","url":"https://clinicaltrials.gov/study/NCT06600841","created_at":"2025-02-26T13:35:01.576Z","updated_at":"2025-02-26T13:35:01.576Z","phase":"Phase 2","brief_title":"Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer","source_id_and_acronym":"NCT06600841","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HRD","pipe":" | ","alterations":" PD-L1 expression • HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-09-19"},{"id":"536366b3-1ab0-4236-bee6-169337ebf109","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413992","created_at":"2024-05-18T04:21:52.082Z","updated_at":"2024-07-02T16:35:03.774Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer","source_id_and_acronym":"NCT06413992","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1 • HRD","pipe":" | ","alterations":" HRD","tags":["PD-L1 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-14"},{"id":"389ebfec-96d0-4ae7-9d59-0a96b42cf326","acronym":"","url":"https://clinicaltrials.gov/study/NCT06208410","created_at":"2024-01-17T18:20:05.757Z","updated_at":"2024-07-02T16:35:15.660Z","phase":"Phase 1/2","brief_title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","source_id_and_acronym":"NCT06208410","lead_sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi) • capecitabine • Irene (pyrotinib) • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 01/11/2024","start_date":" 01/11/2024","primary_txt":" Primary completion: 02/26/2026","primary_completion_date":" 02/26/2026","study_txt":" Completion: 02/26/2026","study_completion_date":" 02/26/2026","last_update_posted":"2024-03-08"},{"id":"aa38eeda-5483-4291-b2f6-f2732467a0db","acronym":"SYSKY-2023-1016-01","url":"https://clinicaltrials.gov/study/NCT06255392","created_at":"2024-02-14T01:28:08.463Z","updated_at":"2024-07-02T16:35:19.550Z","phase":"Phase 3","brief_title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT06255392 - SYSKY-2023-1016-01","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-02-13"},{"id":"d05514ef-5341-4e30-97ff-a3f43a532c21","acronym":"BCTOP-L-A01","url":"https://clinicaltrials.gov/study/NCT05891093","created_at":"2023-06-06T14:07:06.178Z","updated_at":"2024-07-02T16:35:20.130Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","source_id_and_acronym":"NCT05891093 - BCTOP-L-A01","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • AiRuiYi (fluzoparib) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 766","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2031","study_completion_date":" 05/31/2031","last_update_posted":"2024-02-08"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"7e1faa69-bedf-4082-92b9-4c95c81a5274","acronym":"","url":"https://clinicaltrials.gov/study/NCT05753826","created_at":"2023-10-19T19:12:44.189Z","updated_at":"2024-07-02T16:35:20.738Z","phase":"Phase 2","brief_title":"Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.","source_id_and_acronym":"NCT05753826","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-06"},{"id":"faab4dbf-7eb8-4669-87ff-4f8160e576b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05759546","created_at":"2023-03-08T17:01:37.605Z","updated_at":"2024-07-02T16:35:20.716Z","phase":"Phase 2","brief_title":"PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer","source_id_and_acronym":"NCT05759546","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-06"},{"id":"9e070dde-5081-414d-b0de-11e083251a81","acronym":"PRIMA","url":"https://clinicaltrials.gov/study/NCT06074692","created_at":"2023-10-10T14:11:55.368Z","updated_at":"2024-07-02T16:35:30.978Z","phase":"Phase 2","brief_title":"PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)","source_id_and_acronym":"NCT06074692 - PRIMA","lead_sponsor":"Ruijin Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2023-10-31"},{"id":"8a7c54f6-440c-4908-b1b5-80217f424c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT06063070","created_at":"2023-10-02T20:12:38.146Z","updated_at":"2024-07-02T16:35:35.144Z","phase":"Phase 2","brief_title":"First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer","source_id_and_acronym":"NCT06063070","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA wild-type","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2023-10-02"},{"id":"ad93c732-ba36-4a28-a4d6-bf2813bd5cbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06055166","created_at":"2023-09-26T16:12:26.789Z","updated_at":"2024-07-02T16:35:35.791Z","phase":"Phase 2","brief_title":"A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors","source_id_and_acronym":"NCT06055166","lead_sponsor":"Chongqing University Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-09-26"},{"id":"0498e653-58b8-4f7a-ba46-3446c5b95b95","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983237","created_at":"2023-08-09T14:09:26.536Z","updated_at":"2024-07-02T16:35:40.277Z","phase":"Phase 1/2","brief_title":"Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma","source_id_and_acronym":"NCT05983237","lead_sponsor":"Jun Guo","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-11"},{"id":"81289e73-f52b-4e02-9264-0ee67de30fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05585281","created_at":"2022-10-18T14:57:21.085Z","updated_at":"2024-07-02T16:35:41.618Z","phase":"Phase 2","brief_title":"A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy","source_id_and_acronym":"NCT05585281","lead_sponsor":"Yongpeng Wang","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib) • Ankeda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 11/07/2025","primary_completion_date":" 11/07/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2023-07-28"},{"id":"a5bccc88-2f23-45d3-a1c1-0cbe2b9575bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952128","created_at":"2023-07-20T14:08:48.213Z","updated_at":"2024-07-02T16:35:42.594Z","phase":"Phase 2","brief_title":"Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma","source_id_and_acronym":"NCT05952128","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-19"},{"id":"b17610a4-7f1e-4ca3-bde1-2677610463ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05932264","created_at":"2023-07-06T16:10:07.113Z","updated_at":"2024-07-02T16:35:43.864Z","phase":"Phase 2","brief_title":"Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05932264","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • BRAF • ALK • TP53 • ROS1","pipe":" | ","alterations":" TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C","tags":["EGFR • BRAF • ALK • TP53 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-06"},{"id":"d99ff91a-cf24-4676-a6eb-63f5be5bef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05928780","created_at":"2023-07-03T16:10:36.813Z","updated_at":"2024-07-02T16:35:44.110Z","phase":"Phase 1/2","brief_title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)","source_id_and_acronym":"NCT05928780","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib) • AiRuiEn (rezvilutamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-07-03"},{"id":"15efcdbe-273e-4aec-904d-18d868909587","acronym":"","url":"https://clinicaltrials.gov/study/NCT05834582","created_at":"2023-04-28T15:04:40.876Z","updated_at":"2024-07-02T16:35:49.342Z","phase":"Phase 2","brief_title":"Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer","source_id_and_acronym":"NCT05834582","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cyclophosphamide • epirubicin • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/08/2023","start_date":" 04/08/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-04-28"},{"id":"567f80ce-9930-4cef-9968-04c40f134f89","acronym":"IMPARP","url":"https://clinicaltrials.gov/study/NCT05761470","created_at":"2023-03-09T15:01:31.964Z","updated_at":"2024-07-02T16:35:53.649Z","phase":"Phase 2","brief_title":"Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation","source_id_and_acronym":"NCT05761470 - IMPARP","lead_sponsor":"Ying Lin","biomarkers":" HER-2 • BRCA1 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRCA1 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-03-09"},{"id":"754d3aa7-08cc-487d-955b-503562c4f276","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732129","created_at":"2023-02-16T15:00:47.012Z","updated_at":"2024-07-02T16:35:54.764Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05732129","lead_sponsor":"Fudan University","biomarkers":" BRCA1 • HRD • CDK12 • RAD51D","pipe":" | ","alterations":" HRD","tags":["BRCA1 • HRD • CDK12 • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-24"}]